CA1248110A - Piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient - Google Patents

Piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient

Info

Publication number
CA1248110A
CA1248110A CA000477468A CA477468A CA1248110A CA 1248110 A CA1248110 A CA 1248110A CA 000477468 A CA000477468 A CA 000477468A CA 477468 A CA477468 A CA 477468A CA 1248110 A CA1248110 A CA 1248110A
Authority
CA
Canada
Prior art keywords
acid addition
addition salt
acceptable acid
pharmaceutically acceptable
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000477468A
Other languages
English (en)
French (fr)
Inventor
Hiroshi Ohtaka
Toshiro Kanazawa
Keizo Ito
Goro Tsukamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Application granted granted Critical
Publication of CA1248110A publication Critical patent/CA1248110A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA000477468A 1984-03-30 1985-03-26 Piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient Expired CA1248110A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP64,464/84 1984-03-30
JP59064464A JPS60222472A (ja) 1984-03-30 1984-03-30 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
CA1248110A true CA1248110A (en) 1989-01-03

Family

ID=13258978

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000477468A Expired CA1248110A (en) 1984-03-30 1985-03-26 Piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient

Country Status (10)

Country Link
US (1) US4663325A (ref)
EP (1) EP0159566B1 (ref)
JP (1) JPS60222472A (ref)
AT (1) ATE31411T1 (ref)
CA (1) CA1248110A (ref)
DE (1) DE3561199D1 (ref)
ES (3) ES8702393A1 (ref)
FI (1) FI79101C (ref)
GR (1) GR850787B (ref)
NO (1) NO163185C (ref)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61161272A (ja) * 1985-01-11 1986-07-21 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
JPS62277370A (ja) * 1986-02-04 1987-12-02 Terumo Corp ジエン誘導体およびこれを含有する血管拡張剤
FR2614021B1 (fr) * 1987-04-14 1991-03-01 Andre Buzas Derives de la 1-((1,1-diphenyl)-1-alcenyl)-piperazine, procede d'obtention et compositions pharmaceutiques les contenant
DE4108527A1 (de) * 1991-03-15 1992-09-17 Basf Ag Neue 1-(4-cyano-4-aryl-cyclohexyl)piperazine, ihre herstellung und verwendung
AU646926B2 (en) * 1991-03-20 1994-03-10 Duphar International Research B.V. Alkylenedioxyphenyl ether derivatives having anti-ischaemic, memory enhancing and anti-convulsive activity
DE69426871T2 (de) * 1993-12-08 2001-06-21 Alcon Laboratories, Inc. Verbindungen die sowohl starke calcium-antagonistische und antioxydatieve aktivitaet haben und deren verwendung als zellschuetzende mittel.
JP4456269B2 (ja) * 1998-01-29 2010-04-28 ナムローゼ・フェンノートシャップ・オルガノン 視神経乳頭循環改善剤
RU2204556C2 (ru) * 2001-06-18 2003-05-20 Федеральное государственное унитарное предприятие "Новокузнецкий научно-исследовательский химико-фармацевтический институт" Способ получения 1-(парахлорбензгидрил)-4-(2-оксиэтил)пиперазина
OA12905A (en) 2002-08-19 2006-10-13 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
US7433519B2 (en) 2003-04-04 2008-10-07 Avid Technology, Inc. Bitstream format for compressed image data
US7403561B2 (en) 2003-04-04 2008-07-22 Avid Technology, Inc. Fixed bit rate, intraframe compression and decompression of video
WO2004093813A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093816A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
AP1963A (en) * 2003-05-30 2009-03-03 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-co inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7893050B2 (en) * 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
WO2008105442A1 (ja) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド誘導体
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
CN102936233B (zh) * 2012-11-16 2016-01-20 葛长乐 一种1-(二(4-氟苯基)甲基)-4-(2,3,4-三甲氧苯基)哌嗪二盐酸盐晶型
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN107636792B (zh) * 2015-10-20 2019-05-14 韩国标准科学研究院 易于位置调节的电子显微镜用电子枪及包括其的电子显微镜
CN109666008A (zh) * 2018-12-31 2019-04-23 辰欣药业股份有限公司 一种盐酸洛美利嗪的合成方法
PL3911648T3 (pl) 2019-01-18 2025-03-10 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksy)-2- pirymidynylo]amino]cyklopentylo]amino][1(2h),3'-bipirydyn]-2-on jako inhibitor pcsk9 i sposoby jego zastosowania

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB705979A (en) * 1951-03-22 1954-03-24 Henri Morren 1.4-aralkyl piperazines and process for the preparation thereof
FR1312427A (fr) * 1961-04-12 1962-12-21 Science Union Et Compagnie Soc Nouveaux dérivés de la pipérazine et leurs préparations
FR1303080A (fr) * 1961-07-25 1962-09-07 Science Union Et Compagnie Soc Pipérazines disubstituées
NL7306771A (ref) * 1972-06-02 1973-12-04
DE2900810A1 (de) * 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
GB8320701D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent

Also Published As

Publication number Publication date
ES556980A0 (es) 1988-01-01
NO851298L (no) 1985-10-01
FI851217A0 (fi) 1985-03-26
DE3561199D1 (en) 1988-01-28
NO163185C (no) 1990-04-18
ES556981A0 (es) 1988-01-01
JPH0313232B2 (ref) 1991-02-22
JPS60222472A (ja) 1985-11-07
EP0159566A1 (en) 1985-10-30
ES8801237A1 (es) 1988-01-01
FI79101C (fi) 1989-11-10
EP0159566B1 (en) 1987-12-16
FI851217L (fi) 1985-10-01
ES8801236A1 (es) 1988-01-01
FI79101B (fi) 1989-07-31
GR850787B (ref) 1985-11-25
ATE31411T1 (de) 1988-01-15
ES541728A0 (es) 1987-01-01
ES8702393A1 (es) 1987-01-01
US4663325A (en) 1987-05-05

Similar Documents

Publication Publication Date Title
CA1248110A (en) Piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient
CA1199918A (en) 2-¬4-(diphenylmethyl)-1-piperazinyl|-acetic acids and their amides
US4423049A (en) 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
JPH0647586B2 (ja) １−ヘテロアリ−ル−４−〔（２．５−ピロリジンジオン−１−イル）アルキル〕ピペラジン誘導体
CA1317300C (en) Process for the preparation of 2-¬2-¬4-¬(4-chlorophenyl) phenylmethyl|-1-piperazinyl|ethoxy|-acetic acid and its dihydrochloride
KR101639833B1 (ko) 1-［2-（2,4-디메틸페닐술파닐）페닐］피페라진의 정제
EP0395313B1 (en) Tertiary alkyl functionalized piperazine derivatives
PL178546B1 (pl) Nowe, zasadniczo czyste optycznie, enancjomery prawoskrętne lub lewoskrętne 1-[(4-chlorofenylo)fenylometylo] piperazyny i sposób ich wytwarzania
PL116532B1 (en) Process for preparing novel derivatives of amides of 2-methoxy-4-amino-5-alkylsulfonylbenzoic acid
CA2317740A1 (en) Sulphonamide derivatives for treatment of cns disorders
US4367335A (en) Thiazolidinylalkylene piperazine derivatives
CA2085963A1 (en) Benzamide derivatives
CA1240996A (en) Heteroaryl substituted aminomethyl benzene derivatives
HU190827B (en) Process for preparing 2-/4/-/4,4-dialkyl-1,2,6-piperidindion-1-yl/-butyl/-1-piperazinyl/-pyridines
US3948898A (en) 1,3-Dioxo-2-aminoalkyl-4,4-dimethyl-isoquinolines and salts thereof
US4379160A (en) Carbazole compounds and medicinal use thereof
US4529729A (en) Piperazine and homopiperazine compounds
EP0061149A1 (en) Alkylenedioxybenzene derivatives and acid addition salts thereof and a process for their preparation
US4456756A (en) Spirothiazolidinyl piperazine derivatives
US3180867A (en) Piperazine derivatives
CA1338711C (en) Ethanone oximes
US4703048A (en) Novel 1-benzhydryl-4-cinnamylpiperazine derivatives, and pharmaceutical compositions comprising said compounds as active ingredient for treating a cerebrovascular disease
US4528294A (en) Benzoyl-phenyl-piperidine derivatives
JPS5825678B2 (ja) オキサゾ−ルユウドウタイ ノ セイゾウホウ
HU186655B (en) Process for producing new piperidine derivatives, acid additional salts and quaternary salts and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MKEX Expiry